Patents by Inventor Geoffrey Lilley Smith

Geoffrey Lilley Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090143289
    Abstract: An orthopoxvirus vector, such as vaccinia, is described in which the A46R protein from vaccinia, or a closely related protein from any orthopoxvirus is not expressed or is expressed but is non-functional. Also described is the use of a vaccinia virus A46R protein or a closely related protein from any orthopoxvirus, or a functional peptide, peptidometic, fragment or derivative thereof, or a DNA vector expressing any of the above in the modulation and/or inhibition of IL1R/TLR superfamily signalling.
    Type: Application
    Filed: April 30, 2008
    Publication date: June 4, 2009
    Inventors: Luke Anthony John O'Neill, Andrew Graham Bowie, Julianne Stack, Geoffrey Lilley Smith, Ismar Rocha Haga
  • Publication number: 20080299131
    Abstract: The invention provides a composition comprising for simultaneous, sequential or separate administration a) a polyanion; and b) an antibody reactive against an antigen on the surface of an intracellular form of a virus, which virus has an extracellular form that is surrounded by one lipid membrane more than the intracellular form. The present inventors have found that the compositions according to the invention comprising an antibody and a polyanion can neutralize virus infectivity more efficiently than other compositions reported hitherto.
    Type: Application
    Filed: June 28, 2005
    Publication date: December 4, 2008
    Applicant: IMPERIAL INNOVATIONS LIMITED
    Inventors: Geoffrey Lilley Smith, Gemma Chevonne Carter, Mansun Law, Michael Stanley Hollinshead
  • Publication number: 20040082033
    Abstract: HCMV glycoproteins B and H have been identified. The gB protein is encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary. The gH protein is encoded by DNA in the HindIII L fragment lying between 228 and 2456 bases from the L/D boundary.
    Type: Application
    Filed: June 20, 2003
    Publication date: April 29, 2004
    Inventors: Geoffrey Lilley Smith, Martin Patrick Cranage, Barclay George Barrell
  • Patent number: 6610295
    Abstract: HCMV glycoproteins B and H have been identified. The gB protein is encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary. The gH protein is encoded by DNA in the HindIII L fragment lying between 228 and 2456 bases from the L/D boundary. The genes have been incorporated in recombinant vaccinia vectors and expressed in host animals to raise HCMV-neutralizing antibody, thereby indicating vaccine potential. The glycoproteins can also be used in a variety of different ways, as vaccines or in the production, purification or detection of HCMV antibody.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: August 26, 2003
    Assignee: Cogent Limited
    Inventors: Geoffrey Lilley Smith, Martin Patrick Cranage, Barclay George Barrell
  • Patent number: 6162620
    Abstract: HCMV glycoproteins B and H have been identified. The gB protein is encoded by DNA in the HindIII F fragment of the HCMV genome lying between 1378 and 4095 bases from the F/D boundary. The gH protein is encoded by DNA in the HindIII L fragment lying between 228 and 2456 bases from the L/D boundary.The genes have been incorporated in recombinant vaccinia vectors and expressed in host animals to raise HCMV-neutralising antibody, thereby indicating vaccine potential. The glycoproteins can also be used in a variety of different ways, as vaccines or in the production, purification or detection of HCMV antibody.
    Type: Grant
    Filed: July 20, 1994
    Date of Patent: December 19, 2000
    Assignee: Cogent Limited
    Inventors: Geoffrey Lilley Smith, Martin Patrick Cranage, Barclay George Barrell